Clinical trials: Essential,Hypertension
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Essential Hypertension
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values…
- Trial name
- NCT04470830
- Where
- South Korea
- Volunteers
- 718 people
- Sponsor
- Celltrion Pharm, Inc.
Hypertension
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years
- Trial name
- NCT02245464
- Testing
- Telmisartan
- Volunteers
- 13,066 people
- Sponsor
- Boehringer Ingelheim
Hypertension
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with…
- Trial name
- NCT02433119
- Testing
- OROSARTAN® 5/160mg, CODIOVAN® 160/12.5mg
- Where
- South Korea
- Volunteers
- 238 people
- Sponsor
- Dong-A ST Co., Ltd.
Essential Hypertension
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
- Trial name
- NCT00654875
- Testing
- Aliskiren
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 328 people
- Sponsor
- Novartis
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and amlodipine alone in patients with essential hypertension inadequately controlled on amlodipine monotherapy.
- Trial name
- NCT00940667
- Testing
- Amlodipine plus Losartan, Amlodipine
- Where
- South Korea
- Volunteers
- 185 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
- Trial name
- NCT06441630
- Testing
- AD-227A, AD-227B, AD-227C
- Where
- South Korea
- Volunteers
- 251 people
- Sponsor
- Addpharma Inc.
Essential Hypertension, Hypercholesterolemia
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia.
- Trial name
- NCT00254475
- Testing
- simvastatin, valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 871 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
- Trial name
- NCT01876368
- Testing
- LCZ696, Olmesartan
- Where
- 51 sites in United States, Argentina and 5 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides…
- Trial name
- NCT02242825
- Testing
- Micardis®, MicardisPlus®
- Volunteers
- 8,148 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in patients with grade I or II essential hypertension
- Trial name
- NCT02407210
- Testing
- azilsartan, Olmesartan medoxomil
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study_2nd
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01352689
- Testing
- CKD-828(FDC), Combination Therapy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
- Trial name
- NCT00415623
- Testing
- Amlodipine
- Where
- 14 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypertension,Essential
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
- Trial name
- NCT03503773
- Testing
- Alcohol
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 350 people
- Sponsor
- Ablative Solutions, Inc.
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.
- Trial name
- NCT05526703
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension.
- Trial name
- ESAHOM (NCT02612298)
- Testing
- Arotinolol Hydrochloride, Metoprolol succinate sustained-release tablet
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
- Trial name
- NCT07704684
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Amlodipine Group
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical